Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
Targeting the endocannabinoid system: A promising hope for the treatment of Inflammatory bowel Disease...
Current IBD treatments leave many battling uncomfortable symptoms. The bodies natural endocannabanoid system (ECS) is linked to gut health. By targeting the system, researchers believe they will be able to develop novel treatments that tackle inflammation, diarrhea and lingering discomfort. By focusing on this, researchers believe they will be able to develop treatments that tackle both inflammation and lingering discomfort.
Protein kinases for combating inflammatory disease
Julie Blaising, Discovery Project Leader in Immunology at F. Hoffmann-La Roche Ltd, tells us why protein kinases are an effective target for treating many chronic inflammatory disorders.
Roche – biotechnology and in-vitro diagnostics
Roche is a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.
Therapeutic potential of the endocannabinoid system to treat chronic pain in inflammatory disease
Pharma researchers Julie Blaising and Philip Smith from F. Hoffmann-La Roche Ltd. discuss the endocannabinoid system as a pathway to treat inflammatory diseases such as Inflammatory Bowel Disease (IBD) and endometriosis.
MAGL inhibition: A novel treatment option for combating inflammatory disease?
Pharma researchers Uwe Grether and Julie Blaising from F. Hoffmann-La Roche Ltd. highlight the vast therapeutic potential of MAGL inhibition for central and peripheral diseases.
CB₂R ligands to treat inflammatory diseases
Researchers discuss how scientific innovations might influence the discovery of future tailor-made CB2R-based anti-inflammatory treatments.
CB2R agonists in the clinics: A treasure chest for treating inflammatory diseases
Researchers give an update on clinical trials with CB2R agonists and their potential for the treatment of inflammatory diseases.
Targeting the Cannabinoid Type-2 Receptor for Novel Anto-inflammatory Therapeutics
Type-2 cannabinoid receptor (CB2R) is a G-protein-coupled receptor (GPCR) and an essential element of the endocannabinoid system (ECS) [1].
Visualizing the anti-inflammatory cannabinoid Type-2 receptor
Medicinal chemists describe how small molecule probes allow for the detection of CB2R, and thereby enable the discovery of novel anti-inflammatory treatments.
Challenges bringing CB₂R medicine to bedside
Drug hunters explain how to overcome pitfalls on the way to CB2R medicine and therapeutics.
Is CB₂R a hidden treasure trove for treating inflammatory diseases?
Expert scientists working on endocannabinoid system (ECS) trials explain how CB₂R can be used to treat inflammatory diseases.
